

Approved by:



CERTIFICATE

2024

Universitätsklinikum Münster
Gerhard-Domagk-Institut für Pathologie
Domagkstraße 17
48149 Münster
Germany

has successfully completed the proficiency test

BRCA1/2 Mutation Analysis (MolPath)

(Trial Period 02.09.2024 - 20.09.2024)

Berlin, March 12, 2025

Prof. Dr. med. Claudia Wickenhauser
Quality in Pathology - QuIP GmbH

Thomas Pilz, Managing Director
Quality in Pathology - QuIP GmbH

Lead panel institute of the proficiency test:
Dr. rer. nat. N. Pelusi, Prof. Dr. med. V. Tischler, Prof. Dr. med. G. Kristiansen, University Hospital Bonn, Germany

This certificate includes the separate individual evaluation of the test and the corresponding proficiency test report, the evaluation criteria can be found in the proficiency test report under point 3.2.

This proficiency test was organized by:
Qualitätssicherungs-Initiative Pathologie QuIP GmbH /
Reinhardtstr. 1 / 10117 Berlin / office@quip.eu / www.qualityinpathology.com

